Combination antiviral and anti-inflammatory therapy mitigates persistent neurological deficits in mice post SARS-CoV-2 infection

Proceedings of the National Academy of Sciences, Volume 123, Number 2, January 2026.
SignificancePersistent neurological disease after COVID-19 is a major problem, but the underlying mechanism is unclear. Using mouse-adapted SARS-CoV-2, we show that an infection confined to the respiratory tract triggers a lasting loss of dopaminergic…